News

News Subscription

Mar 23. 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Read more
Download
Feb 25. 2026 / Ad hoc announcement
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Read more
Download
Feb 17. 2026 / Ad hoc announcement
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Read more
Download
Feb 09. 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Jan 13. 2026
Basilea joins INCATE to support antifungal innovation
Read more
Download
Jan 08. 2026
Basilea provides portfolio update and outlook
Read more
Download
Jan 07. 2026
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
Read more
Download
Dec 11. 2025
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Read more
Download
Nov 04. 2025 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Read more
Download
Sep 25. 2025 / Ad hoc announcement
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Read more
Download